ClinicalTrials.gg
Enrolling by invitationNCT07849335Updated Sep 30, 2026

Minicrush Versus Culotte Stenting in Complex Coronary Bifurcation Lesions:The Multicenter T-REX II Registry

An observational study in Coronary Artery Disease (CAD), Percutaneous Coronary Intervention (PCI) and Bifurcation Coronary Artery Disease, sponsored by San Luigi Gonzaga Hospital. Enrolling by invitation at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by San Luigi Gonzaga Hospital · Observational

Updated Sep 30, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 302 studies in Coronary Artery Disease with a site in Italy — 48 open to participants now, 71 under way, 7 of them phase 3. Coronary Artery Disease · Italy.

Planned enrollment
49th of 113
500 · median 400
Started
2026
with 6 others
Observational
113 of 302
23 open now
Primary completion
2027-01
later than 44 of 70 live
Registered
301st of 302
by date
Lead sponsor
7 of 302
San Luigi Gonzaga Hospital

Among the 302 studies in Coronary Artery Disease with a site in Italy, this one is the 49th largest by planned enrollment of the 113 observational ones that give a count, is one of 7 that started in 2026, is one of 113 observational ones, reaches primary completion later than 44 of the 70 other live ones, and was the 301st registered.

Coronary Artery Disease

4,863 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

48 of the 302 studies in Coronary Artery Disease with a site in Italy are open now. Recruiting first, the newest first:

43 more — sign in →

All 48 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 588 Coronary Artery Disease studies recruiting now, 402 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 302 studies in Coronary Artery Disease with a site in Italy, or all of them as a file.
02

Study summary

Percutaneous coronary intervention (PCI) of complex coronary bifurcation lesions frequently requires an upfront two-stent strategy. While the double kissing crush technique has been extensively studied, limited contemporary data are available comparing alternative two-stent approaches, particularly Minicrush and T-stenting and Culotte, in complex bifurcation anatomy. This study aimed to compare procedural characteristics and long-term clinical outcomes of Minicrush versus Culotte stenting techniques in patients undergoing PCI for complex coronary bifurcation lesions.

03

Conditions studied

  • Coronary Artery Disease (CAD)
  • Percutaneous Coronary Intervention (PCI)
  • Bifurcation Coronary Artery Disease

Keywords

  • Minicrush
  • Culotte
  • PCI
  • Bifurcation lesions
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This cohort study included all patients with complex coronary bifurcation lesions who received intentional two-stent treatment with the Minicrush or Culotte techniques

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with complex coronary bifurcation lesions according to DEFINITION criteria

Exclusion criteria

Exclusion Criteria:

  • \<18 years
  • Treatment with other techniques
  • Non-complex coronary bifurcation lesions
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • Minicrush Patients

    Culotte Patients

    Procedure: Percutaneous Coronary Intervention with Minicrush

Interventions

  • ProcedurePercutaneous Coronary Intervention with Minicrush

    The Minicrush and Culotte techniques were performed as upfront two-stent strategies according to standard protocols focusing on minimal side-branch stent protrusion and carina reconstruction, respectively.

06

What researchers measure

Primary outcomes

  1. Target Lesion Failure (TLF)

    Composite of cardiac death, Target Vessel Myocardial Infarction and Target Lesion Revascularization

    Time frame: From the enrollment to the end of the study at 5 years

Secondary outcomes

  1. Major Adverse Cardiovascular Events (MACE)

    Composite of all-cause of death, Target vessel Myocardial Infarction and Target Vessel Revascularization

    Time frame: From the enrollment to the endif the treatment at 5 years

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be available for sharing to protect participant privacy and compliance with informed consent limitations.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Jan 2027, 4 months later.

Of 636 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's planned 4 months is below that.

Counting every sponsor, half of 761 studies reached it within 41 months; a quarter within 21 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2026
First posted
Sep 30, 2026
StartEst.
Sep 1, 2026
Primary completionEst.
Jan 1, 2027
CompletionEst.
Apr 1, 2027
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07849335
Lead sponsor
San Luigi Gonzaga Hospital
Responsible party
Enrico Cerrato (MedicalDoctor, San Luigi Gonzaga Hospital) — Principal investigator
First posted
Sep 30, 2026
Start date
Sep 1, 2026 (estimated)
Primary completion
Jan 1, 2027 (estimated)
Completion
Apr 1, 2027 (estimated)
Last update
Sep 30, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion